![Marcella Ruddy](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Marcella Ruddy
Directeur/Membre du Conseil chez POLAREAN IMAGING PLC
Fortune : 571 761 $ au 31/05/2024
Postes actifs de Marcella Ruddy
Sociétés | Poste | Début | Fin |
---|---|---|---|
POLAREAN IMAGING PLC | Directeur/Membre du Conseil | 26/08/2022 | - |
Tectonic Therapeutic, Inc.
![]() Tectonic Therapeutic, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tectonic Therapeutic, Inc., Tectonic Operating Co., Inc. is a company that is transforming the discovery of antibodies and other biologic drugs targeting G-protein coupled receptors (GPCRs) to develop novel therapies for patients inadequately served by current treatments. The company is based in Watertown, MA. With its proprietary Geode™ platform, Tectonic aims to unlock the therapeutic utility of some of the most difficult receptors in the class. The company was founded by Andrew Kruse and Timothy A. Springer. Alise S. Reicin has been the CEO of the company since 2020. Tectonic Operating Co. was acquired by AVROBIO, Inc. on June 20, 2024 for $7.56 million. | Directeur Technique/Scientifique/R&D | 01/07/2021 | - |
MKRuddy Consulting LLC | Directeur/Membre du Conseil | - | - |
Upstream Bio, Inc.
![]() Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | Directeur/Membre du Conseil | 07/02/2023 | - |
Historique de carrière de Marcella Ruddy
Anciens postes connus de Marcella Ruddy
Sociétés | Poste | Début | Fin |
---|---|---|---|
TECTONIC THERAPEUTIC, INC. | Directeur Technique/Scientifique/R&D | 20/06/2024 | - |
Formation de Marcella Ruddy
Washington University in St. Louis | Doctorate Degree |
Princeton University | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 7 |
Royaume-Uni | 2 |
Opérationnelle
Director/Board Member | 3 |
Chief Tech/Sci/R&D Officer | 3 |
Doctorate Degree | 1 |
Sectorielle
Health Technology | 3 |
Commercial Services | 3 |
Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
POLAREAN IMAGING PLC | Health Technology |
Entreprise privées | 4 |
---|---|
Tectonic Therapeutic, Inc.
![]() Tectonic Therapeutic, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tectonic Therapeutic, Inc., Tectonic Operating Co., Inc. is a company that is transforming the discovery of antibodies and other biologic drugs targeting G-protein coupled receptors (GPCRs) to develop novel therapies for patients inadequately served by current treatments. The company is based in Watertown, MA. With its proprietary Geode™ platform, Tectonic aims to unlock the therapeutic utility of some of the most difficult receptors in the class. The company was founded by Andrew Kruse and Timothy A. Springer. Alise S. Reicin has been the CEO of the company since 2020. Tectonic Operating Co. was acquired by AVROBIO, Inc. on June 20, 2024 for $7.56 million. | Commercial Services |
MKRuddy Consulting LLC | |
Upstream Bio, Inc.
![]() Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | Commercial Services |
Avrobio, Inc.
![]() Avrobio, Inc. BiotechnologyHealth Technology AVROBIO, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm's clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis. The company was founded by Geoff Mackay, Kim Warren, Christopher Mason, and Jeffrey Medin in 2015 and is headquartered in Watertown, MA. | Health Technology |
- Bourse
- Insiders
- Marcella Ruddy
- Expérience